These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1771 related items for PubMed ID: 18448208

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H, Liu XF, Zhang X, Chen S, Sun L, Lu J.
    Vaccine; 2007 Oct 16; 25(42):7379-84. PubMed ID: 17870216
    [Abstract] [Full Text] [Related]

  • 3. Generation and evaluation of an H9N1 influenza vaccine derived by reverse genetics that allows utilization of a DIVA strategy for control of H9N2 avian influenza.
    Wu R, Chen Q, Zheng L, Chen J, Sui Z, Guan Y, Chen Z.
    Arch Virol; 2009 Oct 16; 154(8):1203-10. PubMed ID: 19543688
    [Abstract] [Full Text] [Related]

  • 4. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ, Achenbach J, Swayne DE, Donis R, Cox N, Matsuoka Y.
    Vaccine; 2008 Mar 25; 26(14):1742-50. PubMed ID: 18336962
    [Abstract] [Full Text] [Related]

  • 5. Generation and evaluation of reassortant influenza vaccines made by reverse genetics for H9N2 avian influenza in Korea.
    Song JM, Lee YJ, Jeong OM, Kang HM, Kim HR, Kwon JH, Kim JH, Seong BL, Kim YJ.
    Vet Microbiol; 2008 Aug 25; 130(3-4):268-76. PubMed ID: 18374520
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, Shmarov MM, Zhirnov OP, Varich NP, Ilyinskii PO, Shneider AM.
    Arch Virol; 2006 May 25; 151(5):921-31. PubMed ID: 16292596
    [Abstract] [Full Text] [Related]

  • 10. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate.
    Chen H, Subbarao K, Swayne D, Chen Q, Lu X, Katz J, Cox N, Matsuoka Y.
    Vaccine; 2003 May 16; 21(17-18):1974-9. PubMed ID: 12706686
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
    Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA.
    Vaccine; 2007 May 22; 25(21):4283-90. PubMed ID: 17403562
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the classical swine H1N1 subtype influenza virus in mice and pigs.
    Wen F, Yu H, Yang FR, Huang M, Yang S, Zhou YJ, Li ZJ, Tong GZ.
    Arch Virol; 2014 Nov 22; 159(11):2957-67. PubMed ID: 24957653
    [Abstract] [Full Text] [Related]

  • 13. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
    Wodal W, Falkner FG, Kerschbaum A, Gaiswinkler C, Fritz R, Kiermayr S, Portsmouth D, Savidis-Dacho H, Coulibaly S, Piskernik C, Hohenadl C, Howard MK, Kistner O, Barrett PN, Kreil TR.
    Vaccine; 2012 Jun 29; 30(31):4625-31. PubMed ID: 22580355
    [Abstract] [Full Text] [Related]

  • 14. Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza.
    Lee CW, Senne DA, Suarez DL.
    Vaccine; 2004 Aug 13; 22(23-24):3175-81. PubMed ID: 15297071
    [Abstract] [Full Text] [Related]

  • 15. A live bivalent influenza vaccine based on a H9N2 virus strain.
    Wu R, Guan Y, Yang Z, Chen J, Wang H, Chen Q, Sui Z, Fang F, Chen Z.
    Vaccine; 2010 Jan 08; 28(3):673-80. PubMed ID: 19892041
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, Renshaw M, Arpino R, Tamane A, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D.
    Cell Immunol; 2001 Aug 01; 211(2):143-53. PubMed ID: 11591118
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 01; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 89.